{{Drugbox
| IUPAC_name = [1-methyl-5-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1,2,4-triazol-3-yl]methanol
| image = Lavoltidine.svg
| width = 300

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Development terminated
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 76956-02-0
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 55473
| ChemSpiderID = 50093
| UNII = X16K5179V5

<!--Chemical data-->
| C=19 | H=29 | N=5 | O=2 
| molecular_weight = 359.47 g/mol
| smiles = OCc1nn(C)c(n1)NCCCOc2cccc(c2)CN3CCCCC3
}}

'''Lavoltidine''' ([[International Nonproprietary Name|INN]],<ref>{{cite web|title=WHO Drug Information. Vol 4, No. 3, 1990. International Nonproprietary Names for Pharmaceutical Substances. Recommended International Nonproprietary Names (Rec. INN): List 30|url=http://www.who.int/medicines/publications/druginformation/innlists/RL30.pdf|publisher=World Health Organization|accessdate=12 January 2016|page=7}}</ref> [[United States Adopted Name|USAN]], [[British Approved Name|BAN]]; previously known as '''loxtidine''', code name '''AH-23,844''') is a highly [[potency (pharmacology)|potent]] and [[binding selectivity|selective]] [[H2 receptor|H<sub>2</sub> receptor]] [[receptor antagonist|antagonist]] which was under development by Glaxo Wellcome (now [[GlaxoSmithKline]])<ref>{{cite web|title=Drug Profile: Lavoltidine|url=http://adisinsight.springer.com/drugs/800000092|website=AdisInsight|publisher=Springer International Publishing AG|accessdate=12 January 2016}}</ref> as a treatment for [[gastroesophageal reflux disease]] but was discontinued due to the discovery that it produced [[gastric carcinoid tumor]]s in rodents.<ref name="isbn0-8493-5444-7">{{cite book | author = Washington, Neena | title = Antacids and anti-reflux agents | publisher = CRC Press | location = Boca Raton | year = 1991 | pages = | isbn = 0-8493-5444-7 | oclc = | doi = | url = https://books.google.com/books?id=MKxtXgtt5SIC&lpg=PA250&dq=loxtidine&pg=PA250#v=onepage&q&f=false}}</ref><ref name="isbn0-412-54090-8">{{cite book | author = | title = Dictionary of organic compounds | publisher = Chapman & Hall | location = London | year = 1996 | pages = | isbn = 0-412-54090-8 | oclc = | doi = | url = https://books.google.com/books?id=x2Su3GKCvtsC&lpg=PA4087&dq=lavoltidine&pg=PA4087#v=onepage&q&f=false}}</ref>

==See also==
* [[H2 antagonist|H<sub>2</sub> receptor antagonist]]
* [[Sufotidine]] (analogous sequence in which [[sulfone]] replaces the [[hydroxyl]] group)

==References==
{{Reflist}}

{{H2-receptor antagonist}}
{{Histaminergics}}

[[Category:Abandoned drugs]]
[[Category:Alcohols]]
[[Category:Amines]]
[[Category:H2 receptor antagonists]]
[[Category:Piperidines]]
[[Category:Triazoles]]
[[Category:Phenol ethers]]